GLP1R and metabolic dysfunction-associated steatohepatitis: This is particularly relevant as several drugs, such as pioglitazone and glucagon-like peptide-1 (GLP-1) receptor agonists are already being used in individuals with NASH and coexistent T2DM without clear guidance on the most appropriate method for monitoring liver disease in these patients36.